Glioma surveillance imaging—An interview with Dr Sotirios Bisdas

Glioma surveillance imaging—An interview with Dr Sotirios Bisdas

The Power of Imaging in Neuro-Oncology

“The multimodality and combined MRI/PET imaging is expected to provide the necessary framework for personalised treatment regimes, and I’ll put special emphasis here on immunotherapy, and ultimately guidance towards precision oncology…glioma patients will benefit particularly from this approach.”

— Dr Sotirios Bisdas

Dr Sotirios Bisdas, IAG’s Head of Neuro-Oncology and Neurology Clinical Research speaks in the podcast on glioma surveillance imaging. He talks about his recently published paper ‘Glioma surveillance imaging: current strategies, shortcomings, challenges and outlook’ , the various modalities and techniques such as MR perfusion, diffusion, spectroscopy, molecular imaging, as well as multimodality imaging and how he sees the field of clinical research is changing.

Full podcast: here

Full paper: here

About: 

Dr Sotirios Bisdas, Consultant Neuroradiologist and MRI and Clinical Lead at the National Hospital for Neurology in London, Associate Professor in Neuroradiology at the Institute of Neurology, University College London, and Professor of Radiology and Neuroradiology at the University of Tübingen, Germany. He is an expert and a distinguished PI in many international clinical studies, which rely on the use of cutting-edge methodologies and advanced imaging in assessing efficacy of novel treatments for brain tumours and other neurological conditions. He co-authored 130 peer-reviewed publications, 7 book chapters related to advanced MRI in neurological and oncological diseases. He is actively involved in designing and publishing guidelines for the use of perfusion imaging in Oncology.

About IAG, Image Analysis Group

IAG, Image Analysis Group is unique partner to life sciences companies. We leverage our core expertise in medical image analysis, drug development and trial design. We support investors and biotech executive teams with deploying strategies for early drug efficacy assessments, objective response prediction and critical analysis of advanced treatment manifestations. Thus, lowering the investment risks into advanced therapies while helping to accelerate study outcomes. Our Bio-partnering team takes a broader view on the assets’ development and helps to bring our R&D solutions, operational breadth, radiological expertise and deploy these via risk-sharing financing and partnership models.  www.ia-grp.com

 

Engage with our executive team

Dr. Olga Kubassova, CEO, Linkedin here

Schedule call / meeting: imaging.experts@ia-grp.com

Follow the Company: Linkedin

News
Events